ArticleBMC pulmonary medicine2025
Association of metabolic syndrome and prognosis in elderly patients with community-acquired pneumonia.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThis study aimed to evaluate the association between metabolic syndrome (MetS) and clinical outcomes in elderly patients hospitalized with community-acquired pneumonia (CAP).
methodsA retrospective cohort study was conducted on 712 elderly patients (aged ≥ 65 years) admitted with CAP to a tertiary hospital between 2018 and 2022. Patients were stratified into two groups based on MetS status (MetS group vs. non-MetS group). The primary outcome was 90-day all-cause mortality. Propensity score matching (PSM) was applied to balance baseline characteristics. Multivariate Cox regression and logistic regression analyses were performed to assess associations, adjusting for confounders.
resultsAfter propensity score matching, 336 patients (168 MetS and 168 non-MetS) were included in the final analysis. The MetS group had a significantly higher 90-day mortality rate compared to the non-MetS group (29.8% vs. 11.9%, p < 0.01). Multivariate Cox regression analysis demonstrated that MetS was independently associated with a 1.98-fold increased risk of mortality (95% CI: 1.08-3.63; p = 0.03). A clear dose-response relationship was observed, with each additional MetS component increasing mortality risk by 1.46-fold (95% CI: 1.11-2.16; p < 0.01).
conclusionMetS is an independent predictor of worse short-term outcomes in elderly CAP patients, including higher mortality and longer hospital stays. Early recognition and management of MetS may improve prognosis in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.